Fujifilm Holdings Corp. said Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co. to exclusively market its anti-viral drug Avigan for COVID-19 treatment in China.Fujifilm Toyama Chemical Co., a subsidiary of Fujifilm Holdings, will also work with the Chinese pharmaceutical company to develop a form of the drug that can be administered via parenteral injection.Last Friday, the company filed for approval with Japan's health ministry to market Avigan, also known as favipiravir, for COVID-19 treatment.If approved, the drug would be the third treatment in Japan for the resp…READ FULL ARTICLE